Pulse Biosciences (NASDAQ:PLSE) Stock Bumped Down to "Sell" by Wall Street Zen

Key Points

• Wall Street Zen downgraded Pulse Biosciences from Hold to Sell, though analyst sentiment overall remains “Moderate Buy” with an average price target of $66.60.
• Third-quarter results missed expectations: revenue was $400,000, down 54.1% year over year, and the $0.32-per-share loss was slightly wider than forecast.
• Clinical progress offers a counterpoint: the company completed enrollment in its U.S. pivotal study ahead of schedule, but plans to increase quarterly non-GAAP expenses by 15%–25% as it pursues a Q4 2027 CE Mark target.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

Several other equities analysts have also weighed in on PLSE. Freedom Capital upgraded shares of Pulse Biosciences to a "strong-buy" rating in a report on Wednesday, September 9th. BTIG Research assumed coverage on shares of Pulse Biosciences in a research note on Wednesday, September 23rd. They issued a "buy" rating and a $70.00 target price for the company. Needham & Company LLC increased their target price on shares of Pulse Biosciences from $58.00 to $64.00 and gave the stock a "buy" rating in a report on Friday. Weiss Ratings reissued a "sell (d-)" rating on shares of Pulse Biosciences in a research report on Thursday, October 15th. Finally, Mizuho set a $65.00 price target on shares of Pulse Biosciences in a report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $66.60.

Pulse Biosciences Stock Up 0.4%

Shares of NASDAQ PLSE opened at $53.29 on Friday. The business has a fifty day simple moving average of $51.55 and a 200-day simple moving average of $32.28. Pulse Biosciences has a 12 month low of $12.56 and a 12 month high of $58.90.

Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.01). The firm had revenue of $0.40 million for the quarter, compared to the consensus estimate of $0.52 million. Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The firm's revenue was down 54.1% on a year-over-year basis. During the same quarter last year, the company earned ($0.29) earnings per share. Equities research analysts forecast that Pulse Biosciences will post -1.34 EPS for the current year.

Insider Activity at Pulse Biosciences

In other Pulse Biosciences news, COO Liane Teplitsky purchased 1,001 shares of the firm's stock in a transaction on Tuesday, September 1st. The shares were acquired at an average cost of $49.95 per share, for a total transaction of $49,999.95. Following the completion of the transaction, the chief operating officer owned 4,095 shares of the company's stock, valued at approximately $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders have bought 4,095 shares of company stock worth $199,931. 74.00% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Pulse Biosciences

A number of institutional investors have recently modified their holdings of PLSE. Sterling Capital Management LLC raised its holdings in shares of Pulse Biosciences by 844.6% in the 3rd quarter. Sterling Capital Management LLC now owns 614 shares of the company's stock valued at $31,000 after purchasing an additional 549 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in shares of Pulse Biosciences in the second quarter worth about $28,000. Axxcess Wealth Management LLC acquired a new stake in Pulse Biosciences in the 3rd quarter valued at $242,000. Bender Robert & Associates bought a new position in Pulse Biosciences during the third quarter worth about $379,000. Finally, Jupiter Topco LLC bought a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $241,000. 76.95% of the stock is currently owned by institutional investors and hedge funds.

Pulse Biosciences News Roundup

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
• Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
• Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
• Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
• Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage

About Pulse Biosciences

Pulse Biosciences, Inc NASDAQ: PLSE is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company's principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.